-
1
-
-
84857823823
-
-
International Diabetes Federation (Accessed 6 May 2013)
-
International Diabetes Federation. Global diabetes plan 2011-2021; 2012. http://www.idf.org/sites/default/files/Global-Diabetes-Plan-Final.pdf (Accessed 6 May 2013).
-
(2012)
Global Diabetes Plan 2011-2021
-
-
-
2
-
-
84866268783
-
Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes
-
22517736 10.2337/dc12-0413 1:CAS:528:DC%2BC38Xps1Kitb4%3D
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes. Diabetes Care. 2012;35:1364-79.
-
(2012)
Diabetes Care
, vol.35
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
3
-
-
84870765997
-
Year in diabetes 2012: The diabetes tsunami
-
23185035 10.1210/jc.2012-3487 1:CAS:528:DC%2BC38XhvVCgt7vN
-
Sherwin R, Jastreboff AM. Year in diabetes 2012: the diabetes tsunami. J Clin Endocrinol Metab. 2012;97(12):4293-301.
-
(2012)
J Clin Endocrinol Metab
, vol.97
, Issue.12
, pp. 4293-4301
-
-
Sherwin, R.1
Jastreboff, A.M.2
-
4
-
-
78650753885
-
Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications
-
Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124 Suppl.:S3-18.
-
(2011)
Am J Med.
, vol.124
, Issue.SUPPL.
-
-
Nauck, M.A.1
-
5
-
-
67049155251
-
Unraveling the science of incretin biology
-
Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122 Suppl.:S3-10.
-
(2009)
Am J Med.
, vol.122
, Issue.SUPPL.
-
-
Nauck, M.A.1
-
6
-
-
33846006173
-
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
17098089 10.1016/S0140-6736(06)69705-5 1:CAS:528:DC%2BD28XhtF2gurjM
-
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-705.
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
7
-
-
78049365082
-
Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase
-
20709939 10.1124/dmd.110.034066 1:CAS:528:DC%2BC3cXhsVWqurrK
-
Malm-Erjefalt M, Bjornsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38(11):1944-53.
-
(2010)
Drug Metab Dispos
, vol.38
, Issue.11
, pp. 1944-1953
-
-
Malm-Erjefalt, M.1
Bjornsdottir, I.2
Vanggaard, J.3
-
8
-
-
84861765116
-
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
-
22432104 10.2337/dc11-1935 1:CAS:528:DC%2BC38Xps1Kit7g%3D
-
Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225-31.
-
(2012)
Diabetes Care
, vol.35
, Issue.6
, pp. 1225-1231
-
-
Fonseca, V.A.1
Alvarado-Ruiz, R.2
Raccah, D.3
-
9
-
-
0142179159
-
Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice
-
10.1124/jpet.103.051987
-
Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther. 2003;302(2):490-6.
-
(2003)
J Pharmacol Exp Ther
, vol.302
, Issue.2
, pp. 490-496
-
-
Thorkildsen, C.1
Neve, S.2
Larsen, B.D.3
-
10
-
-
77955847376
-
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
-
20570597 10.1016/j.regpep.2010.05.008 1:CAS:528:DC%2BC3cXhtVKhtbfE
-
Werner U, Haschke G, Herling AW, et al. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164(2-3):58-64.
-
(2010)
Regul Pept
, vol.164
, Issue.2-3
, pp. 58-64
-
-
Werner, U.1
Haschke, G.2
Herling, A.W.3
-
11
-
-
84891642041
-
Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes
-
23423907 10.1007/s12325-013-0009-4 1:CAS:528:DC%2BC3sXjslOgsr0%3D
-
Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther. 2013;30(2):81-101.
-
(2013)
Adv Ther
, vol.30
, Issue.2
, pp. 81-101
-
-
Horowitz, M.1
Rayner, C.K.2
Jones, K.L.3
-
12
-
-
84886586625
-
Combination of lixisenatide and insulin glargine demonstrates complementary pharmacological activity on glycemic control in animal models of diabetes [abstract no.1051-p]
-
Werner U, Gerlach M, Hofmann M, et al. Combination of lixisenatide and insulin glargine demonstrates complementary pharmacological activity on glycemic control in animal models of diabetes [abstract no.1051-p]. Diabetes. 2012;61 Suppl.1:A270.
-
(2012)
Diabetes.
, vol.61
, Issue.SUPPL.1
-
-
Werner, U.1
Gerlach, M.2
Hofmann, M.3
-
13
-
-
77952118055
-
-
European Medicines Agency (Accessed 8 Apr 2013)
-
European Medicines Agency. Lixisenatide: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002445/WC500140401.pdf (Accessed 8 Apr 2013).
-
(2013)
Lixisenatide: Summary of Product Characteristics
-
-
-
14
-
-
84878863716
-
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes inadequately controlled on metformin
-
10.1111/dom.12076 1:CAS:528:DC%2BC3sXptFelsbo%3D
-
Kapitza C, Forst T, Coester H-V, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes inadequately controlled on metformin. Diabetes Obes Metabol. 2013;15(7):642-9.
-
(2013)
Diabetes Obes Metabol
, vol.15
, Issue.7
, pp. 642-649
-
-
Kapitza, C.1
Forst, T.2
Coester, H.-V.3
-
15
-
-
84878878831
-
Restitution of glucose disposition with lixisenatide in subjects with type 2 diabetes [abstract no.813]
-
Becker RH, Kapitza C, Stechl J, et al. Restitution of glucose disposition with lixisenatide in subjects with type 2 diabetes [abstract no.813]. Diabetologia. 2012;55 Suppl.1:S335-S6.
-
(2012)
Diabetologia
, vol.55
, Issue.SUPPL. 1
-
-
Becker, R.H.1
Kapitza, C.2
Stechl, J.3
-
16
-
-
84868242234
-
Restoration of insulin release with lixisenatide in patients with type 2 diabetes [abstract no. 850]
-
Becker RHA, Ruus P, Li YH, et al. Restoration of insulin release with lixisenatide in patients with type 2 diabetes [abstract no. 850]. Diabetologia. 2010;53 Suppl.1:S339.
-
(2010)
Diabetologia
, vol.53
, Issue.SUPPL. 1
-
-
Becker, R.H.A.1
Ruus, P.2
Li, Y.H.3
-
17
-
-
84879128093
-
Augmentation of first-phase insulin release with lixisenatide in nondiabetic subjects [abstract no. 814]
-
Stechl J, Becker RH, Kapitza C, et al. Augmentation of first-phase insulin release with lixisenatide in nondiabetic subjects [abstract no. 814]. Diabetologia. 2012;55:S336.
-
(2012)
Diabetologia
, vol.55
, pp. 336
-
-
Stechl, J.1
Becker, R.H.2
Kapitza, C.3
-
18
-
-
84885135014
-
Post-meal pharmacodynamic profile of lixisenatide once daily vs placebo in T2DM insufficiently controlled on SU ± metformin (GetGoal-S) [abstract no. D-0743]
-
Dubai; 4-8 Dec
-
Ratner RE, Hanefeld M, Shamanna P, et al. Post-meal pharmacodynamic profile of lixisenatide once daily vs placebo in T2DM insufficiently controlled on SU ± metformin (GetGoal-S) [abstract no. D-0743]. 21st World Congress of the International Diabetes Federation, Dubai; 4-8 Dec 2011.
-
(2011)
21st World Congress of the International Diabetes Federation
-
-
Ratner, R.E.1
Hanefeld, M.2
Shamanna, P.3
-
19
-
-
84878549237
-
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes: Relationship to postprandial glycemia
-
10.1016/j.regpep.2013.04.001
-
Lorenz M, Pfeiffer C, Steinstraser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes: relationship to postprandial glycemia. Regul Peptides. 2013;185C:1-8.
-
(2013)
Regul Peptides
, vol.185
, pp. 1-8
-
-
Lorenz, M.1
Pfeiffer, C.2
Steinstraser, A.3
-
20
-
-
84878859924
-
Anti-atherosclerotic activity of lixisenatide in ApoE knockout mice [abstract no. 809]
-
Hubschle T, Schafer HL, Juretschke HP, et al. Anti-atherosclerotic activity of lixisenatide in ApoE knockout mice [abstract no. 809]. Diabetologia. 2012;55 Suppl.1:S334.
-
(2012)
Diabetologia.
, vol.55
, Issue.SUPPL. 1
-
-
Hubschle, T.1
Schafer, H.L.2
Juretschke, H.P.3
-
21
-
-
84875299548
-
Cardioprotective effects of lixisenatide in rat myocardial ischaemia-reperfusion injury studies
-
23537041 10.1186/1479-5876-11-84 1:CAS:528:DC%2BC3sXnvVyjurk%3D
-
Wohlfart P, Linz W, Hubschle T, et al. Cardioprotective effects of lixisenatide in rat myocardial ischaemia-reperfusion injury studies. J Transl Med. 2013;11:84.
-
(2013)
J Transl Med
, vol.11
, pp. 84
-
-
Wohlfart, P.1
Linz, W.2
Hubschle, T.3
-
22
-
-
84878857616
-
Effect of GLP-1 receptor agonist AVE0010 on the absorption of concomitant oral drugs: Acetaminophen and ethinylestradiol/levonorgestrel [abstract no. 776]
-
Vienna; 29 Sep-2 Oct
-
Liu Y-H, Ruus P. Effect of GLP-1 receptor agonist AVE0010 on the absorption of concomitant oral drugs: acetaminophen and ethinylestradiol/ levonorgestrel [abstract no. 776]. 45th Annual Meeting of the European Association for the Study of Diabetes, Vienna; 29 Sep-2 Oct 2009.
-
(2009)
45th Annual Meeting of the European Association for the Study of Diabetes
-
-
Liu, Y.-H.1
Ruus, P.2
-
24
-
-
84886594743
-
Interaction of subcutaneous lixisenatide 20 μg QD on pharmacokinetic and pharmacodynamic properties of oral ramipril 5 mg QD [abstract]
-
Dahmen R, Steinstraesser A, Poitiers F, et al. Interaction of subcutaneous lixisenatide 20 μg QD on pharmacokinetic and pharmacodynamic properties of oral ramipril 5 mg QD [abstract]. Basic Clin Pharmacol Toxicol. 2011;109 Suppl.:89.
-
(2011)
Basic Clin Pharmacol Toxicol
, vol.109
, Issue.SUPPL.
, pp. 89
-
-
Dahmen, R.1
Steinstraesser, A.2
Poitiers, F.3
-
25
-
-
84878622377
-
Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1) [abstract no. 784]
-
Bolli G, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1) [abstract no. 784]. Diabetologia. 2011;54(Suppl. 1):S316-7.
-
(2011)
Diabetologia
, vol.54
, Issue.SUPPL. 1
-
-
Bolli, G.1
Munteanu, M.2
Dotsenko, S.3
-
26
-
-
84878358313
-
Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)
-
10.2337/dc12-2006 23536584
-
Ahren B, Leguizamo A, Miossec P, et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013. doi: 10.2337/dc12-2006.
-
(2013)
Diabetes Care
-
-
Ahren, B.1
Leguizamo, A.2
Miossec, P.3
-
27
-
-
84887589926
-
Lixisenatide in Asian patients with type 2 diabetes (T2DM) uncontrolled on metformin ± sulfonylurea (SU): GetGoal-M Asia [abstract no. PCS-20-3]
-
Pan CY, Zhao Q, Niemoeller E. Lixisenatide in Asian patients with type 2 diabetes (T2DM) uncontrolled on metformin ± sulfonylurea (SU): GetGoal-M Asia [abstract no. PCS-20-3]. J Diabetes Invest. 2012;3 Suppl.1:204.
-
(2012)
J Diabetes Invest
, vol.3
, Issue.SUPPL.1
, pp. 204
-
-
Pan, C.Y.1
Zhao, Q.2
Niemoeller, E.3
-
28
-
-
84871148091
-
Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S) [abstract no. 785]
-
Ratner RE, Hanefeld M, Shamanna P, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S) [abstract no. 785]. Diabetologia. 2011;54 Suppl.1:S317.
-
(2011)
Diabetologia
, vol.54
, Issue.SUPPL.1
-
-
Ratner, R.E.1
Hanefeld, M.2
Shamanna, P.3
-
29
-
-
84885331631
-
Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
-
doi: 10.1111/dom.12121
-
Pinget M, Goldenberg R, Niemoeller E, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013. doi: 10.1111/dom.12121.
-
(2013)
Diabetes Obes Metab.
-
-
Pinget, M.1
Goldenberg, R.2
Niemoeller, E.3
-
30
-
-
84878592117
-
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
-
10.2337/dc12-2454
-
Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013. doi: 10.2337/dc12-2454.
-
(2013)
Diabetes Care
-
-
Riddle, M.C.1
Aronson, R.2
Home, P.3
-
31
-
-
84865979163
-
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
-
22564709 10.1111/j.1463-1326.2012.01618.x 1:CAS:528:DC%2BC38XhtlSmtLzO
-
Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910-7.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.10
, pp. 910-917
-
-
Seino, Y.1
Min, K.W.2
Niemoeller, E.3
-
32
-
-
84878603672
-
Adding once-daily lixisenatide in type 2 diabetes inadequately controlled with newly initiated insulin and continuously titrated basal insulin glargine: A 24-week, randomized, placebo-controlled study (GetGoal-DUO-l)
-
10.2337/dc12-2462
-
Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide in type 2 diabetes inadequately controlled with newly initiated insulin and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-DUO-l). Diabetes Care. 2013. doi: 10.2337/dc12-2462.
-
(2013)
Diabetes Care
-
-
Riddle, M.C.1
Forst, T.2
Aronson, R.3
-
33
-
-
84883324640
-
Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
-
10.2337/dc12-2709
-
Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013. doi: 10.2337/dc12-2709.
-
(2013)
Diabetes Care
-
-
Rosenstock, J.1
Raccah, D.2
Koranyi, L.3
-
34
-
-
84885138356
-
-
European Medicines Agency (Accessed 8 Apr 2013)
-
European Medicines Agency. Assessment report Lyxumia. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/002445/WC500140449.pdf (Accessed 8 Apr 2013).
-
(2012)
Assessment Report Lyxumia
-
-
-
39
-
-
77955887980
-
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled trial
-
20722676 10.1111/j.1464-5491.2010.03020.x 1:CAS:528:DC%2BC3cXht1aqsLjN
-
Ratner RE, Rosenstock J, Boka G, et al. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010;27(9):1024-32.
-
(2010)
Diabet Med
, vol.27
, Issue.9
, pp. 1024-1032
-
-
Ratner, R.E.1
Rosenstock, J.2
Boka, G.3
-
40
-
-
84886589723
-
Efficacy and safety of lixisenatide in elderly (≥65 years) and very elderly (≥75 years) patients with type 2 diabetes: An analysis from the GetGoal Phase 3 programme [abstract no. 815]
-
Raccah D, Miossec P, Esposito V, et al. Efficacy and safety of lixisenatide in elderly (≥65 years) and very elderly (≥75 years) patients with type 2 diabetes: an analysis from the GetGoal Phase 3 programme [abstract no. 815]. Diabetologia. 2012;55 Suppl.1:S336.
-
(2012)
Diabetologia
, vol.55
, Issue.SUPPL.1
-
-
Raccah, D.1
Miossec, P.2
Esposito, V.3
-
41
-
-
84885124311
-
Long-term (up to 2 years) safety of lixisenatide once daily vs placebo in T2DM insufficiently controlled on metformin (GetGoal-F1) [abstract no. O-0595]
-
Dubai; 4-8 Dec
-
Bolli G, Munteanu M, Dotsenko S, et al. Long-term (up to 2 years) safety of lixisenatide once daily vs placebo in T2DM insufficiently controlled on metformin (GetGoal-F1) [abstract no. O-0595]. 21st World Congress of the International Diabetes Federation, Dubai; 4-8 Dec 2011.
-
(2011)
21st World Congress of the International Diabetes Federation
-
-
Bolli, G.1
Munteanu, M.2
Dotsenko, S.3
-
44
-
-
84864970211
-
Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: A systematic review and meta-analysis
-
22912709 10.1371/journal.pone.0042551 1:CAS:528:DC%2BC38Xht1Srs7nP
-
Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2012;7(8):e42551.
-
(2012)
PLoS ONE
, vol.7
, Issue.8
, pp. 42551
-
-
Zhang, Y.1
Hu, G.2
Yuan, Z.3
-
45
-
-
66749181130
-
Postprandial hyperglycaemia as an etiological factor in vascular failure
-
19402896 10.1186/1475-2840-8-23
-
Node K, Inoue T. Postprandial hyperglycaemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009;8:23.
-
(2009)
Cardiovasc Diabetol
, vol.8
, pp. 23
-
-
Node, K.1
Inoue, T.2
-
46
-
-
0042166232
-
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c)
-
12610053 10.2337/diacare.26.3.881
-
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-5.
-
(2003)
Diabetes Care
, vol.26
, Issue.3
, pp. 881-885
-
-
Monnier, L.1
Lapinski, H.2
Colette, C.3
-
47
-
-
0035675342
-
Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: The epidemiological evidence
-
11793012 10.1007/s001250100020 1:CAS:528:DC%2BD3MXovFWitb4%3D
-
Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44(12):2107-14.
-
(2001)
Diabetologia
, vol.44
, Issue.12
, pp. 2107-2114
-
-
Bonora, E.1
Muggeo, M.2
-
48
-
-
0032511583
-
Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatments and risk of complications in patients with type 2 diabetes
-
UK Prospective Diabetes Study (UKPDS) Group 10.1016/S0140-6736(98)07019-6
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatments and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-53.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
49
-
-
70349881450
-
Intensive glucose control and macrovascular outcomes in type 2 diabetes
-
19655124 10.1007/s00125-009-1470-0 1:CAS:528:DC%2BD1MXht1Cis7jI
-
Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-98.
-
(2009)
Diabetologia
, vol.52
, Issue.11
, pp. 2288-2298
-
-
Turnbull, F.M.1
Abraira, C.2
Anderson, R.J.3
-
50
-
-
65649106228
-
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials
-
19465231 10.1016/S0140-6736(09)60697-8 1:CAS:528:DC%2BD1MXmtleksbc%3D
-
Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765- 72.
-
(2009)
Lancet
, vol.373
, Issue.9677
, pp. 1765-1772
-
-
Ray, K.K.1
Seshasai, S.R.2
Wijesuriya, S.3
-
51
-
-
70349124205
-
Systematic review: Glucose control and cardiovascular disease in type 2 diabetes
-
19620144 10.7326/0003-4819-151-6-200909150-00137
-
Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151(6):394-403.
-
(2009)
Ann Intern Med
, vol.151
, Issue.6
, pp. 394-403
-
-
Kelly, T.N.1
Bazzano, L.A.2
Fonseca, V.A.3
-
52
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
18784090 10.1056/NEJMoa0806470 1:CAS:528:DC%2BD1cXht1Wgt7nK
-
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
-
(2008)
N Engl J Med
, vol.359
, Issue.15
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
-
53
-
-
4644351335
-
Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
-
15381515 10.7326/0003-4819-141-6-200409210-00007 1:CAS:528: DC%2BD2cXos1Cjtrk%3D
-
Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421-31.
-
(2004)
Ann Intern Med
, vol.141
, Issue.6
, pp. 421-431
-
-
Selvin, E.1
Marinopoulos, S.2
Berkenblit, G.3
-
54
-
-
77449089099
-
Glycemic control and complications in type 2 diabetes mellitus
-
20206730 10.1016/j.amjmed.2009.12.004 1:CAS:528:DC%2BC3cXivFalsLs%3D
-
Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123:S3-11.
-
(2010)
Am J Med
, vol.123
-
-
Stolar, M.1
-
55
-
-
74349097849
-
Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
-
20456169 10.1111/j.1742-1241.2009.02227.x
-
Del Prato S, LaSalle J, Matthaei S, et al. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract. 2010;64(3):295-304.
-
(2010)
Int J Clin Pract
, vol.64
, Issue.3
, pp. 295-304
-
-
Del Prato, S.1
Lasalle, J.2
Matthaei, S.3
-
56
-
-
33846706458
-
The loss of prandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes
-
17259492 10.2337/dc06-1612
-
Monnier L, Colette C, Dunseath GJ, et al. The loss of prandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30(2):263-9.
-
(2007)
Diabetes Care
, vol.30
, Issue.2
, pp. 263-269
-
-
Monnier, L.1
Colette, C.2
Dunseath, G.J.3
-
57
-
-
84859033619
-
Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes
-
22028279 10.2337/dc11-0632 1:CAS:528:DC%2BC38XhtVaktA%3D%3D
-
Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-14.
-
(2011)
Diabetes Care
, vol.34
, Issue.12
, pp. 2508-2514
-
-
Riddle, M.1
Umpierrez, G.2
Digenio, A.3
-
59
-
-
79951631623
-
Patient adherence to medication requirements for therapy of type 2 diabetes
-
21314869 10.1111/j.1742-1241.2010.02544.x 1:STN:280: DC%2BC3M7ovVOlsQ%3D%3D
-
Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314-22.
-
(2011)
Int J Clin Pract
, vol.65
, Issue.3
, pp. 314-322
-
-
Bailey, C.J.1
Kodack, M.2
-
60
-
-
79955432850
-
-
European Medicines Agency (Accessed 10 May 2013)
-
European Medicines Agency. Forxiga: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002322/WC500136026.pdf (Accessed 10 May 2013).
-
(2013)
Forxiga: Summary of Product Characteristics
-
-
-
61
-
-
84885142360
-
-
Janssen Pharmaceuticals Inc. (Accessed 10 May 2013)
-
Janssen Pharmaceuticals Inc. Invokana™: US prescribing information. 2013. http://www.invokanahcp.com/prescribing-information.pdf (Accessed 10 May 2013).
-
(2013)
Invokana™: US Prescribing Information
-
-
-
62
-
-
79960262492
-
Management of type 2 diabetes: New and future developments in the treatment
-
21705062 10.1016/S0140-6736(11)60207-9 1:CAS:528:DC%2BC3MXos1GrsLk%3D
-
Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in the treatment. Lancet. 2011;378:182-97.
-
(2011)
Lancet
, vol.378
, pp. 182-197
-
-
Tahrani, A.A.1
Bailey, C.J.2
Del Prato, S.3
-
63
-
-
84859030635
-
SGLT2 inhibitors: A new emerging class in the treatment of type 2 diabetes mellitus
-
21543663 10.1177/0091270011400604 1:CAS:528:DC%2BC38XmsFers7c%3D
-
Ghosh RK, Ghosh SM, Chawla S, et al. SGLT2 inhibitors: a new emerging class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52:457-63.
-
(2012)
J Clin Pharmacol
, vol.52
, pp. 457-463
-
-
Ghosh, R.K.1
Ghosh, S.M.2
Chawla, S.3
-
64
-
-
83655193529
-
The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia
-
10.1111/j.1463-1326.2011.01511.x 1:CAS:528:DC%2BC38XhvFOmsLw%3D
-
DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metabol. 2012;14:5-14.
-
(2012)
Diabetes Obes Metabol
, vol.14
, pp. 5-14
-
-
Defronzo, R.A.1
Davidson, J.A.2
Del Prato, S.3
-
65
-
-
79959796830
-
Impact of the US Food and Drug Administration cardiovascular assessment requirements on the drug development of novel antidiabetes drugs
-
Hirshberg B, Raz I. Impact of the US Food and Drug Administration cardiovascular assessment requirements on the drug development of novel antidiabetes drugs. Diabetes Care. 2011;34 Suppl.2:S101-6.
-
(2011)
Diabetes Care.
, vol.34
, Issue.SUPPL. 2
-
-
Hirshberg, B.1
Raz, I.2
-
67
-
-
84876063836
-
Glucagon like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus
-
23440284 10.1001/jamainternmed.2013.2720 1:CAS:528:DC%2BC3sXmt1ektr0%3D
-
Singh S, Chang H-Y, Richards TM, et al. Glucagon like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus. JAMA Intern Med. 2013;173(7):534-9.
-
(2013)
JAMA Intern Med
, vol.173
, Issue.7
, pp. 534-539
-
-
Singh, S.1
Chang, H.-Y.2
Richards, T.M.3
-
68
-
-
84878352363
-
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors
-
23524641 10.2337/db12-1686 1:CAS:528:DC%2BC3sXhtFWjsbzM
-
Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595-604.
-
(2013)
Diabetes
, vol.62
, pp. 2595-2604
-
-
Butler, A.E.1
Campbell-Thompson, M.2
Gurlo, T.3
-
69
-
-
79959559653
-
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
-
21334333 10.1053/j.gastro.2011.02.018 1:CAS:528:DC%2BC3MXosVGnsrY%3D
-
Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-6.
-
(2011)
Gastroenterology
, vol.141
, pp. 150-156
-
-
Elashoff, M.1
Matveyenko, A.V.2
Gier, B.3
-
70
-
-
84879231610
-
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks
-
10.2337/dc12-2504
-
Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013. doi: 10.2337/dc12-2504.
-
(2013)
Diabetes Care
-
-
Nauck, M.A.1
|